GET DAILY SIGNALSWhy Is Schrödinger (SDGR) Stock Up +13.44% Today?
Key Takeaways
- SDGR shares climbed roughly 13.44% in Tuesday's session, building on a multi-day rally that has carried the stock near its 52-week high.
- The primary catalyst was a broad surge across AI-driven drug discovery names, with no single company-specific announcement explaining the move.
- Secondary drivers include a steady stream of analyst price-target increases in recent weeks and momentum ahead of the company's upcoming earnings report.
- The rally in SDGR was part of a wider rotation into computational and AI-enabled biotech software names rather than a response to macro headlines.
- Traders are watching the company's third-quarter results, scheduled for release after the close on November 4, 2026.
- For deeper analysis of SDGR, explore its Price Targets, Earnings, and Forecast pages for additional data and insights.
- Looking for algorithmic trading ideas? Explore the Trending AI Robots section to see which automated strategies are performing best under current market conditions.
Opening Summary
Schrödinger, Inc. (SDGR), a developer of physics-based computational software for drug discovery and materials science, saw its shares jump sharply on Tuesday, gaining approximately 13.44% to trade near $30.31, up from a prior-session close of $26.72. The advance extended a powerful run that has lifted the stock more than 25% over five sessions and positioned it within striking distance of its 52-week high. Markets attributed the move primarily to a broad rally across artificial intelligence-driven drug discovery stocks, rather than to any single piece of company news.
AI Drug Discovery Sector Rally
The clearest driver behind Tuesday's gain was a coordinated surge across the AI-enabled drug discovery complex. Names including Absci, Recursion Pharmaceuticals, Twist Bioscience, Tempus AI, and 10x Genomics all advanced between roughly 8% and 12%, with SDGR leading the group. Notably, no company-specific disclosure explained the synchronized move, suggesting that renewed investor appetite for risk and enthusiasm around AI's role in accelerating pharmaceutical research were the dominant forces behind the sector-wide buying.
Schrödinger stands out within this cohort because it carries the most substantial underlying business. The company generated approximately $255.9 million in revenue in 2025, up about 23% from the prior year, giving investors a tangible revenue base to anchor valuation against — a contrast with several earlier-stage peers whose rallies are more closely tied to sentiment.
Analyst Target Raises and Momentum
A series of upward revisions from sell-side analysts in recent weeks helped set the stage for the move. BMO Capital, TD Cowen, and KeyCorp each raised their price targets during October, with objectives ranging from $30 to $32. As SDGR surged past the consensus analyst target, the stock increasingly traded on momentum rather than on conventional valuation headroom, a dynamic that can amplify short-term gains in either direction.
The rally also carries technical significance. The stock has climbed well above its 50-day moving average, which sat near the mid-$24 range, and its momentum has left it up more than 175% from its 52-week low of $10.95. The next widely watched level is the 52-week high of $33.78.
Market Context and Trading Activity
Trading activity across the AI drug discovery group was notably heavy on Tuesday, consistent with a broad reallocation of capital into the theme. The strength was largely idiosyncratic to the sector, as the move was driven by industry-specific enthusiasm rather than a uniformly bullish tape in the broader market. For SDGR, the advance extended a rally that has already far outpaced the major indices this year, underscoring the stock's high-beta, momentum-sensitive profile.
What Comes Next for SDGR
The next major catalyst for SDGR arrives on November 4, 2026, when the company reports third-quarter results after the market close. Analysts have penciled in a loss per share and a modest revenue figure that would represent a year-over-year decline, a forecast that contrasts with the upside surprise the company delivered in its most recent quarter. That tension between conservative Street estimates and recent execution momentum adds to the volatility priced into the stock into the print.
Beyond earnings, investors will watch for updates on the company's software bookings and drug discovery collaborations, as well as any further analyst actions. Risks include the possibility that the run has moved ahead of fundamentals, thin-volume follow-through in prior sessions, and the stock's sensitivity to any pullback in risk appetite across the AI-enabled biotech space.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that are currently demonstrating the strongest performance. While Tickeron offers hundreds of bots covering thousands of tickers, this section features only those performing best under present market conditions. Each bot differs by strategy, timeframe, performance metrics, and the symbols it trades, giving traders a range of automated approaches to explore.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SDGR in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 07, 2026
SDGR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 24 of 27 cases where SDGR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 66 cases where SDGR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on SDGR as a result. In 72 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
SDGR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +12.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where SDGR advanced for three days, in 213 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 147 of 187 cases where SDGR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for SDGR moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 25 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Moving Average Convergence Divergence Histogram (MACD) for SDGR turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 40 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
The 10-day moving average for SDGR crossed bearishly below the 50-day moving average on October 26, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SDGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.076) is normal, around the industry mean (4.353). SDGR has a moderately low P/E Ratio (-36.603) as compared to the industry average of (13.253). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. P/S Ratio (6.835) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. SDGR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SDGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of chemical simulation software solutions to pharmaceutical industry.
Industry ServicestotheHealthIndustry
Advertisement